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Abstract: To test the hypothesis that digital clubbing in patients 
with lung cancer reflects elevated systemic levels of prostaglandin E
2 
(PGE
2
), we quantified levels of the major urinary PGE
2
 metabolite in 
29 patients with lung cancer with or without clubbing. We found that 
digital clubbing was associated with markedly elevated urinary lev-
els of PGE
2
 metabolite. These findings highlight a potential role for 
PGE
2
 in the pathogenesis of digital clubbing. Furthermore, this result 
identifies a lung cancer subpopulation that may uniquely benefit from 
cyclooxygenase inhibition.
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The cause of digital clubbing has been a medical mys-tery since it was first recognized in the fifth century BC. 
Here we present evidence from a prospective study for the 
molecular pathogenesis of clubbing and discuss its potential 
therapeutic implications. Several lines of evidence suggest a 
role for the cyclooxygenase (COX) metabolite, prostaglandin 
E
2
 (PGE
2
), in the etiology of digital clubbing and hypertro-
phic osteoarthropathy (HOA). First, observations that HOA is 
commonly found in patients with pathologic shunting around 
the pulmonary circulation led to the hypothesis that a cir-
culating factor, normally inactivated in the lung, is central to 
HOA pathogenesis. Prostaglandins fit this profile as they are 
subject to first-pass catabolism in lung by 15-hydroxyprosta-
glandin dehydrogenase.1,2 Second, PGE
1
 treatment leads to 
signs of HOA in infants with cyanotic heart disease and in 
adults with liver disease.2,3 Third, primary HOA has recently 
been linked to inactivating mutations in the gene encoding 
15-hydroxyprostaglandin dehydrogenase.2 Finally, marked ele-
vations in the major urinary PGE
2
 metabolite, 11α-hydroxy-9, 
15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (PGE-M), 
were recently reported in a lung cancer patient with HOA.1 In 
this patient, symptoms of HOA, including debilitating bilateral 
leg pain, were completely relieved by the COX-2 inhibitor, rofe-
coxib, and promptly recurred with rofecoxib discontinuation.
PATIENTS AND METHODS
A prospective study of urine PGE-M levels in newly diag-
nosed, adult patients with stage III/IV lung cancer with and with-
out digital clubbing was initiated at the Massachusetts General 
Hospital Thoracic Oncology Clinic. Twenty-nine patients were 
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FIGURE 1. Clubbing in a patient with lung cancer. Scham­
roth’s sign, or the obliteration of the normal window at the 
base of opposed nail beds, is evident in the lower panel.
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accrued. To limit pharmacologic confounding, patients who had 
taken aspirin, nonsteroidal antiinflammatories, or corticosteroids 
within 14 days, 3 days, and 30 days, respectively, were excluded 
from the study. Time restrictions were selected to reflect agent 
half lives. Similarly, patients with dialysis-dependent renal fail-
ure or systemic inflammatory illness were excluded. Clubbing 
was identified by clinical examination by a single physician 
with extensive experience managing patients with thoracic 
malignancies (K.R.K.). Examination included simple visual 
inspection and Schamroth’s test (Figure 1).4 Importantly, club-
bing was coded before obtaining urine. The study was approved 
by the Partners Human Subjects Research Committee. Patients 
provided written informed consent. Urine was obtained before 
initiation of therapy. Urine was desedimented by centrifugation 
and stored at –78°C until analysis. Urine PGE-M levels were 
measured in duplicate as described previously.5
RESULTS AND CONCLUSIONS
Patient characteristics, urine PGE-M levels, and distri-
bution of clubbing among patient subgroups are presented in 
Table 1. Significantly elevated levels of urinary PGE-M were 
detected in patients with clubbing. The median urinary PGE-M 
level was 2.3-fold higher in patients with clubbing compared 
with patients without clubbing (data not shown). Statistically 
significant differences in urinary PGE-M levels were not 
detected when patients were segregated by smoking status, 
gender, cancer stage, or cancer histology. Fisher’s exact test 
testing revealed no statistically significant imbalances in smok-
ing status, gender, cancer stage, or cancer histology between 
patients with clubbing and patients without clubbing. Age did 
not vary significantly between patients with or without clubbing 
(clubbing: 60 ± 4 years and no clubbing: 64 ± 3 years; p = 0.47, 
Wilcoxon rank sum test). Multivariate linear regression analysis 
with the logarithm of urinary PGE-M as the dependent variable 
yielded clubbing as the only significant covariate (p = 0.017); 
gender was of borderline significance (p = 0.07).
This study affirms our hypothesis that clubbing in 
patients with lung cancer is significantly associated with ele-
vated levels of PGE
2
. In the context of the evidence described 
earlier in the text, these data suggest that PGE
2
 may be caus-
ally linked to clubbing and HOA. Promising preclinical data 
prompted interest in COX-2 inhibitors in lung cancer therapy. 
Nevertheless, clinical trials demonstrated poor efficacy in 
unselected patients.6 Some evidence indicates that COX-2 
inhibitors may specifically benefit those patients with lung 
cancers that express high levels of COX-2 (and thus produce 
large quantities of PGE
2
). Our data suggest that simple visual 
inspection of the digits may identify patients with lung cancer 
more likely to benefit from COX-2 inhibitors.
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TABLE 1. Patient Characteristics, Urine PGE­M (Average ± SE), and Clubbing Distribution 
among Patient Subgroups
 
Number (%)
Urinary  
PGE-M (ng/mg Cr) pa
Number with 
Clubbing pb
Clubbing
 Yes 10 (34) 62 ± 20 0.03 — —
 No 19 (66) 24 ± 5  — —
Smoking status
 Current 11 (38) 45 ± 18 0.41 6/11 0.11
 Not current 18 (62) 33 ± 8  4/18  
Gender
 Male 8 (28) 60 ± 24 0.09 3/8 1.0
 Female 21 (72) 29 ± 6  7/21  
Cancer stage
 III 15 (52) 23 ± 4 0.16 3/15 0.13
 IV 14 (48) 53 ± 15  7/14  
Histology
 Adenocarcinoma 17 (59) 48 ± 13 0.24 7/17 0.45
 Other 12 (41) 22 ± 5  3/12  
a Wilcoxon rank sum test.
b Fisher’s exact test.
PGE-M, prostaglandin E
2
 metabolite
